Because NTSR1 functions as an oncogene and NTS-NTSR1 signaling is a potential target of anti-cancer therapy, methylation of NTSR1 could be a predictive biomarker of the responsiveness of CRC patients to such treatment. Here, NTSR1 is linked to cancer.